Top in endocrinology: Metformin plus Mediterranean diet; lean mass loss with GLP-1s
A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean diet intervention.
Cumulative incidence of noncommunicable diseases appeared significantly lower among those who received metformin with or without a Mediterranean diet intervention.
“[Daily metformin] is effective in the prevention of diabetes, but not other NCDs, in people selected on the basis of metabolic syndrome,” Patrizia Pasanisi, MD, director of nutritional and metabolomic research at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, and colleagues wrote.
It was the top story in endocrinology last week.
In another top story, a systematic review and meta-analysis of nine randomized controlled trials revealed that lean mass comprised 30.8% of total body weight lost among adults receiving GLP-1 therapy.
Read these and more top stories in endocrinology below:
Daily metformin prevents type 2 diabetes among patients with metabolic syndrome
Participants with metabolic syndrome who received 1,700 mg metformin daily with or without a Mediterranean diet intervention had reduced incidence of diabetes compared with placebo, according to findings published in Diabetes Care. Read more.
About 31% of weight lost by adults during GLP-1 therapy comes from lean mass
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled trial, according to findings published in Obesity. Read more.
Most adults with overweight or obesity discontinue GLP-1 therapy within 2 years
More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported in JAMA Network Open. Read more.
FDA approves new indication for Ozempic to lower kidney risks in type 2 diabetes, CKD
The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney disease, Novo Nordisk announced. Read more.
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with an increase in online searches for obesity drugs, according to data published in JAMA Network Open. Read more.